Ubiquitination of p53 is involved in troglitazone induced apoptosis in cervical cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 2313-2318

  Chen, Hui Min ^a   Zhang, Ding Guo ^a   Wu, Jin Xia ^a   Pei, Dong Sheng ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cervix; P53; PPAR ; Troglitazone; Ubiquitination of p53

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MDM2 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN MDM2; PROTEIN P53; TROGLITAZONE;

APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; HUMAN; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS;

EID: 84899046669     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.2313     Document Type: Article

References (28)

1. Canbay E, Kurnaz O, Canbay B, et al (2012). PPAR-gamma Pro12Ala polymorphism and gastric cancer risk in a Turkish population. Asian Pac J Cancer Prev, 13, 5875-8.
2. Cheon CW, Kim DH, Kim DH, Cho YH, Kim JH (2009). Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol, 15, 310-20.
3. Choi HH, Gully C, Su CH, et al (2011). COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3sigma. Oncogene, 30, 4791-801.
4. Dong YW, Wang XP, Wu K (2009). Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol, 15, 441-8.
5. Han S, Roman J (2006). Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther, 5, 430-7.
6. Hasan TN, B LG, Shafi G, Al-Hazzani AA, Alshatwi AA (2011). Anti-proliferative effects of organic extracts from root bark of Juglans Regia L. (RBJR) on MDA-MB-231 human breast cancer cells: role of Bcl-2/Bax, caspases and Tp53. Asian Pac J Cancer Prev, 12, 525-30.
7. Hassan ZK, Elamin MH, Omer SA, et al (2013). Oleuropein induces apoptosis via the p53 pathway in breast cancer cells. Asian Pac J Cancer Prev, 14, 6739-42.
8. Jung TI, Baek WK, Suh SI, et al (2005). Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol, 97, 365-73.
9. Kawa S, Nikaido T, Unno H, et al (2002). Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas, 24, 1-7.
10. Kim S, Lee JJ, Heo DS (2011). PPARgamma ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. Biochem Bioph Res Com, 406, 389-95.
11. Li M, LeeTW, MokTS, et al (2005). Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem, 96, 760-74.
12. Li Y, Zhang S, Geng JX, and Hu XY (2013). Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Asian Pac J Cancer Prev, 14, 4599-602.
13. Liu JJ, Huang RW, Lin DJ, et al (2005). Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol, 16, 455-9.
14. Matsuyama M, and Yoshimura R (2009). A novel approach to anticancer therapies: peroxisome proliferator activator-receptor-gamma as a new target therapy in the treatment of human urological cancer. Endocr Metab Immune Disord Drug Targets, 9, 76-83.
15. Nagamine M, Okumura T, Tanno S, et al (2003). PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci, 94, 338-43.
16. Nagata D, Yoshihiro H, Nakanishi M, et al (2008). Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev, 32, 259-66.
17. Nam DH, Ramachandran S, Song DK, et al (2007). Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone. Mol Hum Reprod, 13, 829-36.
18. Ohtani S, Kagawa S, Tango Y, et al (2004). Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. Mol Cancer Ther, 3, 93-100.
19. Okamoto K, Taya Y, Nakagama H (2009). Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. Febs Lett, 583, 2710-4.
20. Park JW, Zarnegar R, Kanauchi H, et al (2005). Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid, 15, 222-31.
21. Pei DS, Yang ZX, Zhang BF, et al (2012). Enhanced apoptosis-inducing function of MDA-7/IL-24 RGD mutant via the increased adhesion to tumor cells. J Interferon Cytokine Res, 32, 66-73.
22. Tian H, Wang J, Zhang B, et al (2012). MDA-7/IL-24 induces Bcl-2 denitrosylation and ubiquitin-degradation involved in cancer cell apoptosis. Plos One, 7, e37200.
23. Ueno T, Teraoka N, Takasu S, et al (2012). Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. Asian Pac J Cancer P, 13, 4067-73.
24. Wu JS, Lin TN, Wu KK (2009). Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol, 220, 58-71.
25. Yoshimura R, Matsuyama M, Segawa Y, et al (2003). Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer, 104, 597-602.
26. Yu J, Qiao L, Zimmermann L, et al (2006). Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology, 43, 134-43.
27. Zaytseva YY, Wallis NK, Southard RC, Kilgore MW (2011). The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and-independent mechanisms. Anticancer Res, 31, 813-23.
28. Zhou YM, Wen YH, Kang XY, et al (2008). Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol, 14, 2168-73.